The European Haemophilia Consortium on Innovation and Patient Access
The European Haemophilia Consortium (EHC) represents patient organisations from 49 European nations, advocating for equitable access to bleeding‑disorder treatments. CEO Olivia Romero Lux highlighted the shift from plasma‑derived products to recombinant factors, non‑factor therapies and gene therapy, while noting persistent gaps in diagnosis and care. EHC’s strategy blends advocacy, education, and capacity‑building, targeting HTA involvement, women’s health, ultra‑rare conditions, and holistic patient support. The group seeks transparent partnerships with industry and regulators to ensure innovation reaches all patients, regardless of geography or wealth.
How ASGCT and OTXL Are Working to Revive Shelved Cell and Gene Therapies
The American Society of Gene & Cell Therapy (ASGCT) and Orphan Therapeutics Accelerator (OTXL) have launched CGTxchange, an AI‑driven matchmaking platform designed to revive cell and gene therapies that were shelved for ultra‑rare diseases. By aggregating confidential and public data...
How Real-World Evidence Is Shaping Inclusive Clinical Trials with Takeda CMO Dr. Awny Farajallah — Episode 257
In the latest Xtalks Life Science Podcast, Takeda CMO Dr. Awny Farajallah explains how real‑world evidence (RWE) is reshaping clinical trial design to be more inclusive and diverse. He highlights the use of RWE in rare‑disease programs such as narcolepsy...
The Most Expensive Drugs on the Market in 2026 — and Why They Cost So Much
In 2026 the United States market is dominated by ultra‑high‑priced one‑time gene and cell therapies, with Lenmeldy leading at $4.25 million per patient. Other top‑tier products include Hemgenix ($3.5 M), Elevidys ($3.2 M), Lyfgenia ($3.1 M) and Skysona ($3 M). Reuters notes the median list...
10 Obesity Drug Companies to Watch in 2026
Obesity drug development is diversifying beyond injectable GLP‑1s, with companies pursuing oral pills, dual/triple agonists and amylin‑based therapies. Major players such as Eli Lilly and Novo Nordisk are expanding pipelines—Lilly’s retatrutide delivered up to 28% weight loss in Phase III, while Novo’s oral...
The Lily Foundation’s Strategy to Transform Mitochondrial Disease Research
The Lily Foundation, created after founder Liz Curtis lost her daughter Lily to a mitochondrial disease, is tackling the rare disorder’s diagnostic and therapeutic gaps. It funds patient‑focused support, backs early‑stage research, and sponsors a precision‑diagnostics project that uses advanced...
IBio’s Global Clinical Trial Strategy for Advancing Next-Gen Obesity Drugs
iBio is advancing next‑generation obesity therapeutics that go beyond GLP‑1 weight‑loss drugs, focusing on muscle preservation, durability, tolerability, and cardiometabolic complications. The company secured Australian regulatory clearance for a Phase I trial of IBIO‑600, a long‑acting anti‑myostatin antibody designed for infrequent...
World Blood Cancer Day 2026: New FDA Approvals and Phase III Readouts
World Blood Cancer Day 2026 highlights a projected 180,000 new U.S. blood‑cancer cases, underscoring the disease’s growing burden. The FDA granted several approvals, including an all‑oral decitabine/cedazuridine‑venetoclax regimen for older AML patients and Beqalzi for relapsed mantle‑cell lymphoma. Janssen’s Tecvayli...
World Schizophrenia Day 2026: New Data, Tests & Treatment Targets
On World Schizophrenia Day, new data reveal a rising US prevalence of about 3.07 million adults and a 60% increase in diagnoses among youth. The article spotlights several mid‑ to late‑stage drug programs—a muscarinic M1/M4 agonist, a PDE10A inhibitor, and a...
The Colorectal Cancer Alliance’s Efforts to Improve Screening, Awareness and Outcomes
The Colorectal Cancer Alliance, led by CEO Michael Sapienza, is accelerating research and early detection through its Project Cure CRC initiative, which has funded 33 projects in the past 18 months. The Alliance is launching an adaptive clinical‑trial platform to...
Pharma and Biotech M&As 2026 Deal Watcher
The pharma and biotech sector kicked off 2026 with a wave of high‑value mergers, building on a record‑setting 2025 that saw roughly $240 billion in deal value. Notable transactions include Angelini’s $4.1 billion acquisition of Catalyst to enter the U.S. rare‑disease market,...
Stem Cell Therapies for Degenerative Disc Disease and More with BioRestorative’s Lance Alstodt — Episode 256
In the latest Xtalks Life Science Podcast, BioRestorative Therapies CEO Lance Alstodt discussed the company’s stem‑cell‑based programs targeting degenerative disc disease and metabolic disorders. Alstodt highlighted over 25 years of experience in med‑tech, capital raising, and M&A, positioning BioRestorative to...
How Ossium Health Is Building an Off-the-Shelf Bone Marrow Transplant Model
Ossium Health is developing an off‑the‑shelf bone‑marrow product sourced from deceased organ donors, aiming to eliminate the timing and dose constraints of traditional live‑donor transplants. The company’s first‑in‑human PRESERVE I trial has treated about 25 patients with cryopreserved marrow and...
ADAA’s Vision for Anxiety and Depression Care in 2026 and Beyond
The Anxiety & Depression Association of America (ADAA) outlined its 2025‑2028 strategic plan, emphasizing brand elevation, evidence‑based practice, and deeper member engagement. Recent milestones include the launch of the open‑access Journal of Mood and Anxiety Disorders and the rollout of...
Airway Therapeutics CEO on Rethinking Bronchopulmonary Dysplasia Trials
Airway Therapeutics is advancing zelpultide alfa, an investigational biologic aimed at preventing bronchopulmonary dysplasia (BPD) in extremely preterm infants born between 22 and 27 weeks gestation. CEO Marc Salzberg highlighted the clinical and operational hurdles of neonatal trials, including limited...